Cat. No.: HY-135146

GSK-3484862

Name: GSK-3484862
Brand: MedChemExpress
SKU: HY-135146
Price: 55.00 USD
Availability: InStock
Rating: 5 (26 reviews)

(Synonyms: (R)-GSK3482364)

26 Cited Publications

Customer Review

Based on 26 publication(s) in Google Scholar

GSK-3484862 is a highly potent non-covalent inhibitor and demethylating agent of DNMT1. GSK-3484862 induces genome-wide DNA demethylation, including the regulatory elements of DNMT3B and the promoter region of TERT, and significantly inhibits cell viability, growth, proliferation and self-renewal. GSK-3484862 blocks the transformation of young AT2 cells, induces apoptosis, and generates transcriptomic features similar to those of senescent cells. GSK-3484862 is widely used in studies related to lung cancer, oral squamous cell carcinoma and lung adenocarcinoma.

For research use only. We do not sell to patients.

Purity : 99.95%
CAS No.: 2170136-65-7
Formula: C₁₉H₁₉N₅OS
Molecular Weight:365.45

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months

GSK-3484862 Chemical Structure

CAS No.: 2170136-65-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- IC₅₀ & Target
- In Vitro
- In Vivo
Chemical Information
Publications (26)
Solvent & Solubility
- In Vitro
- In Vivo
Protocols (11)
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

IC₅₀ & Target

DNMT1

All DNA Methyltransferase Isoforms :

In Vitro

GSK-3484862 (2 μM, 10 μM; 6 days) induces global DNA demethylation in mouse embryonic stem cells, reducing the global CpG methylation level of the cells from nearly 70% to less than 18%, and the methylation pattern after induction is similar to that of Dnmt1^-/- deficient mouse embryonic stem cells^[1].
GSK-3484862 (1-10 μM; 1 week) inhibits proliferation, promotes apoptosis, and reduces the self-renewal capacity of Cal27 and FaDu oral squamous cell carcinoma (OSCC) cells by downregulating the expression of DNMT1^[2].
GSK-3484862 inhibits the in vitro transformation of primary alveolar type 2 cells isolated from young KP-Cas9 mice, but has no effect on alveolar type 2 cells from aged KP-Cas9 mice, and induces the expression of Nupr1 and Lcn2 in this system^[3].
GSK-3484862 induces hypomethylation at specific CpG sites in Nupr1 enhancers (E1, E7, E8), which correlates with upregulated Nupr1 gene expression^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.

Cell Viability Assay^[2]

View Protocol

Cell Line:

Murine embryonic stem cells (mESC, wild-type (WT) or Dnmt1/3a/3b triple knockout (TKO))
Concentration:

2 µM and 10 µM
Incubation Time:

6 or 14 days
Result:

Induced dramatic DNA methylation loss, with global CpG methylation levels falling from near 70% in WT mESC to less than 18% after 6 days.

Western Blot Analysis^[2]

View Protocol

Cell Line:

Murine embryonic stem cells (mESC, wild-type (WT) or Dnmt1/3a/3b triple knockout (TKO))
Concentration:

2 µM and 10 µM
Incubation Time:

4 days
Result:

Resulted in a modest reduction in DNMT1 protein level.

In Vivo

Systemic administration of GSK-3484862 for 8 days reduces DNA methylation levels in AT2 cells of young mice and induces a senescence-like transcriptome, including upregulation of Nupr1 and Lcn2^[3].
Systemic administration of GSK-3484862 inhibits the transformation of AT2 cells in young mice, but has no such effect on AT2 cells in aged mice, while it induces the expression of Nupr1 and Lcn2 in cells from both age groups^[3].
GSK-3484862 induces pyroptosis of tumor cells in the mouse 4T1 breast cancer model^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Chemical Information

CAS No. 2170136-65-7
Appearance Solid
Molecular Weight 365.45
Formula C₁₉H₁₉N₅OS
Color White to light yellow
SMILES

O=C(N)[C@H](SC1=NC(N(C)C)=C(C#N)C(CC)=C1C#N)C2=CC=CC=C2
Synonyms

(R)-GSK3482364
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Publications (26)

All Flow CytometryBio/Physico-chemical AssayIFRT-PCR

Sort by:

Journal Impact Factor

Nat Genet

DNA sequence and chromatin modifiers cooperate to confer epigenetic bistability at imprinting control regions. [Abstract]

2022 Nov;54(11):1702-1710. PMID: 36333500

GSK-3484862 purchased from MedChemExpress. Usage Cited in: Nat Genet. 2022 Nov;54(11):1702-1710. [Abstract]

Flow cytometric analysis of three independent clones with the methylated Airn-CAG reporter after 2 days treatment with the DNA methylation inhibitor GSK-3484862 (10 µM) and untreated and DMSO controls. Measurements were repeated 7 days after washout of the drug to test for reversion of the reporter silencing.
Nat Commun

A biallelically active embryonic enhancer dictates GNAS imprinting through allele-specific conformations. [Abstract]

2025 Feb 5;16(1):1377. PMID: 39910084

GSK-3484862 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Feb 5;16(1):1377. [Abstract]

WT hESCs were treated with a DNTM1 inhibitor (DNMT1i), GSK-3484862, 10 µM for 17 days.
Nat Commun

Motif distribution and DNA methylation underlie distinct Cdx2 binding during development and homeostasis. [Abstract]

2025 Jan 22;16(1):929. PMID: 39843425

GSK-3484862 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 22;16(1):929. [Abstract]

Fluorescence micrographs showing loss of DNA methylation in cells upon treatment with inhibitor GSK-3484862 (10 μM) for 6 days, (4 independent experiments).

GSK-3484862 purchased from MedChemExpress. Usage Cited in: Nat Commun. 2025 Jan 22;16(1):929. [Abstract]

Representative genomic track showing fractional methylation of CpGs within ACTA1 gene body in HCT116 cells. Lollipop plots show 14 consecutive CpGs within 10 random representative amplicon sequences (from > 100× coverage on nanopore amplicon bisulfite sequencing) and their methylation status upon DMSO or GSK-3484862 (10 µM) treatment and 3 days of recovery; average methylation of all sequenced amplicons (>100× coverage) is represented for all treatment conditions in the right panel.
Nat Commun

Priming a vascular-selective cytokine response permits CD8+ T-cell entry into tumors. [Abstract]

2023 Apr 14;14(1):2122. PMID: 37055433
Nat Ecol Evol

Gene body methylation suppresses intragenic transcription and permits epigenetic inheritance in a cnidarian. [Abstract]

2026 Jun 2. PMID: 42231006
Nucleic Acids Res

Single-molecule tracking of DNMT1 in living cells reveals its cell cycle dynamics and its redistribution upon drug treatment. [Abstract]

2026 Feb 5;54(4):gkag089. PMID: 41641704
Nucleic Acids Res

The C-terminal 4CXXC-type zinc finger domain of CDCA7 recognizes hemimethylated DNA and modulates activities of chromatin remodeling enzyme HELLS. [Abstract]

2024 Sep 23;52(17):10194-10219. PMID: 39142653
Nucleic Acids Res

Uncovering the roles of DNA hemi-methylation in transcriptional regulation using MspJI-assisted hemi-methylation sequencing. [Abstract]

2024 Mar 21;52(5):e24. PMID: 38261991
J Clin Invest

The long-range interaction between two GNAS imprinting control regions delineates pseudohypoparathyroidism type 1B pathogenesis. [Abstract]

2023 Apr 17;133(8):e167953. PMID: 36853809

GSK-3484862 purchased from MedChemExpress. Usage Cited in: J Clin Invest. 2023 Apr 17;133(8):e167953. [Abstract]

WT hESCs were treated with 2 μM GSK-3484862 for 2 days. Following the removal of GSK3484862, genomic DNA was purified at the indicated time points, and methylation levels at upstream (UP) and downstream (DOWN) of A/B DMR, MCTS2, PEG10, and KCNQ1OT1 were calculated by MSRE-qPCR. The results showed that in the hESCs, methylation levels at the A/B DMR decreased substantially by day 4 following a 2-day treatment with GSK-3484862 (14.1% and 9.2% methylation for the UP and DOWN regions, respectively).
Adv Sci (Weinh)

Targeted SPP1 Inhibition of Tumor-Associated Myeloid Cells Effectively Decreases Tumor Sizes. [Abstract]

2025 Jan;12(4):e2410360. PMID: 39639496
Cell Death Dis

Growth factor receptor plasticity drives therapeutic persistence of metastatic breast cancer. [Abstract]

2025 Apr 4;16(1):251. PMID: 40185706
Environ Sci Technol

Retinal Degeneration Response to Graphene Quantum Dots: Disruption of the Blood-Retina Barrier Modulated by Surface Modification-Dependent DNA Methylation. [Abstract]

2024 Aug 20;58(33):14629-14640. PMID: 39102579
Arch Toxicol

Integrative genome-wide aberrant DNA methylation and transcriptome analysis identifies diagnostic markers for colorectal cancer. [Abstract]

2025 May;99(5):2179-2196. PMID: 40059124
Mol Cancer Res

A druggable UHRF1/DNMT1/GLI complex regulates Sonic hedgehog dependent tumor growth. [Abstract]

2022 Nov 3;20(11):1598-1610. PMID: 35925047
Drug Dev Res

Sustained DNA Hypomethylation Induced by a DNA Methyltransferase 1 Inhibitor Triggers Apoptosis in Thyroid Cancer Cells. [Abstract]

2026 May;87(3):e70299. PMID: 42048599
J Biochem

DAXX promotes SUMOylation of chromatin-trapped DNMT1. [Abstract]

2026 Feb 13:mvag011. PMID: 41679964
J Oral Biosci

Exploring the Role of DNMT1 in Dental Papilla Cell Fate Specification during Mouse Tooth Germ Development through Integrated Single-Cell Transcriptomics and Bulk RNA Sequencing. [Abstract]

2024 Sep;66(3):530-538. PMID: 38942194
bioRxiv

2026 Jun 15.
bioRxiv

Regulation of BCL11A DNA binding and expression in human erythrocyte precursor HUDEP-2 cells. [Abstract]

2026 Feb 8:2026.02.06.704516. PMID: 41822826
bioRxiv

2025 Nov 14.
bioRxiv

Divergent roles of DNA methylation, TRIM28, and p53 surveillance in human embryonic and trophoblast stem cells. [Abstract]

2025 Oct 20:2025.10.19.683051. PMID: 41279747
bioRxiv

2025 April 08.
Patent

US20240252638A1.
biorxiv

2024 Jun 07.
bioRxiv

Quinoline-based compounds can inhibit diverse enzymes that act on DNA. [Abstract]

2024 Apr 3:2024.04.03.587980. PMID: 38617249
bioRxiv

September 13, 2021.

Solvent & Solubility

In Vitro:

DMSO : 20 mg/mL (54.73 mM; ultrasonic and warming and heat to 60°C; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

2.7364 mL

13.6818 mL

27.3635 mL

5 mM

0.5473 mL

2.7364 mL

5.4727 mL

10 mM

0.2736 mL

1.3682 mL

2.7364 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: 2.08 mg/mL (5.69 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 2.08 mg/mL (5.69 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.08 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocols

All Cell Biology Signal Pathway Related

Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
CCK-8/WST-8 Cell Proliferation Assay
The CCK-8/WST-8 assay is based on the reduction of the water-soluble tetrazolium salt WST-8 to a water-soluble formazan product by cellular dehydrogenases in metabolically active cells, where the generated formazan amount is proportional to the number of living cells and is quantified by measuring absorbance in the visible range, providing a colorimetric readout for cell viability and proliferation assessment. This class of tetrazolium-based assays improves upon earlier MTT-based systems by producing a water-soluble formazan, eliminating the need for organic solubilization steps and enabling direct spectrophotometric measurement in culture medium.
MTT Cell Proliferation Assay
The MTT assay is a colorimetric endpoint assay for estimating viable cell number, cell growth, cytotoxicity, or cell activation in cultured mammalian cells. Living cells reduce the yellow tetrazolium salt MTT into purple/blue formazan, while dead cells do not generate the same signal; the resulting color can be quantified with a multiwell spectrophotometer. MTT reduction is commonly interpreted as a readout of metabolic activity that often correlates with viable cell number, but it should not be treated as a direct cell-counting method unless the assay is optimized for the cell type and experimental condition. Studies show that MTT reduction can involve mitochondrial and non-mitochondrial reducing systems, and formazan may accumulate in intracellular lipid droplets rather than simply marking mitochondria.
hPSC maintenance and expansion
This protocol maintains and expands human pluripotent stem cells under feeder-free, chemically defined conditions using E8 medium and vitronectin-coated culture surfaces; the readout is sustained adherent colony growth with undifferentiated morphology and retained pluripotency-marker expression during serial passaging. E8-based hPSC culture relies on defined soluble factors and matrix-dependent adhesion rather than feeder cells; vitronectin supports hPSC attachment through integrin-mediated interactions, and EDTA passaging dissociates colonies as small aggregates without enzymatic digestion, centrifugation, or routine ROCK-inhibitor treatment.
Senescence-associated β-galactosidase staining
Senescence-associated β-galactosidase staining detects β-galactosidase activity that is histochemically visible at pH 6. 0 in senescent cells, where X-gal cleavage produces an insoluble blue precipitate observable by bright-field microscopy. This activity reflects increased lysosomal β-galactosidase/lysosomal mass rather than a senescence-essential enzyme, because GLB1 depletion or genetic lysosomal β-galactosidase deficiency can abolish SA-β-gal staining while cells still undergo senescence. SA-β-gal was originally reported in senescent but not presenescent fibroblasts and keratinocytes, absent from quiescent fibroblasts and terminally differentiated keratinocytes, and increased with donor age in human skin samples. Because SA-β-gal can also appear in some non-senescent or tissue-specific contexts, interpretation should be paired with experimental controls and, when possible, independent senescence markers.
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (282 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Azevedo Portilho N, et al. The DNMT1 inhibitor GSK-3484862 mediates global demethylation in murine embryonic stem cells. Epigenetics Chromatin. 2021;14(1):56. Published 2021 Dec 15. [Content Brief]

[2]. Liu Y, et al. DNMT1-targeting remodeling global DNA hypomethylation for enhanced tumor suppression and circumvented toxicity in oral squamous cell carcinoma. Mol Cancer. 2024;23(1):104. Published 2024 May 16. [Content Brief]

[3]. Zhuang X, et al. Aging limits stemness and tumorigenesis in the lung by reprogramming iron homeostasis[J]. BioRxiv, 2024: 2024.06. 23.600305.

[4]. Chen Q, et al. GSK-3484862, a DNMT1 degrader, promotes DNMT3B expression in lung cancer cells. NAR Cancer. 2025;7(2):zcaf018. Published 2025 May 27. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	2.7364 mL	13.6818 mL	27.3635 mL	68.4088 mL
	5 mM	0.5473 mL	2.7364 mL	5.4727 mL	13.6818 mL
	10 mM	0.2736 mL	1.3682 mL	2.7364 mL	6.8409 mL
	15 mM	0.1824 mL	0.9121 mL	1.8242 mL	4.5606 mL
	20 mM	0.1368 mL	0.6841 mL	1.3682 mL	3.4204 mL
	25 mM	0.1095 mL	0.5473 mL	1.0945 mL	2.7364 mL
	30 mM	0.0912 mL	0.4561 mL	0.9121 mL	2.2803 mL
	40 mM	0.0684 mL	0.3420 mL	0.6841 mL	1.7102 mL
	50 mM	0.0547 mL	0.2736 mL	0.5473 mL	1.3682 mL

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

GSK-3484862

Publications Citing Use of MedChemExpress (MCE) GSK-3484862

All DNA Methyltransferase Isoforms